Delivery Order SPE2DB20D6037-SPE2DB25FTVC9

Award Date 4/7/25
Potential Completion Date 4/8/25
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,842.75, is for the delivery of the pharmaceutical item "ZEPBOUND 10 MG/0.5 ML PEN 0.5ML" and has an ultimate completion date of September 9, 2024. The contract is issued under the DLA's SPE2DB program, which is an indefinite delivery contract (IDC) valued at up to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $11,438.70, is for the supply of the pharmaceutical product ZEPBOUND 5 MG/0.5 ML PEN 0.5ML. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at $499,999,999 and valid through...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,671.91, is for the provision of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of January 17, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,705.03 contract is for the delivery of ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with an ultimate completion date of April 1, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $3,685.50, is for the delivery of a specialty pharmaceutical product called ZEPBOUND 5 MG/0.5 ML PEN 0.5ML. It is a part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group, valued at $499,999,999, which enables the DLA to issue delivery orders for a comprehensive...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has an ultimate completion date of February 20, 2025, and a ceiling value of $6,863.22. The contract covers the provision of ZEPBOUND 10 MG/0.5 ML PEN 0.5ML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc....
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $1,580.64 and a completion date of July 19, 2024. The contract falls under the DLA's SPE2DB program, which is a single-award indefinite delivery contract (IDC) valued at up to $499,999,999 and running through December 31, 2025. Under this IDC, DMS...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,211.30, is for the supply of ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of November 19, 2024. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML, a specialized pharmaceutical product, with a ceiling value of $3,812.90 and a period of performance through February 10, 2025. The contract is a firm fixed-price delivery order and is not associated with any set-aside designation,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $7,625.80 and is valid through February 27, 2025. It covers the delivery of the pharmaceutical product "ZEPBOUND 5 MG/0.5 ML PEN 0.5ML" to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a significant...
  • SPE2DB20D6037
    Indefinite Delivery Contract
  • SPE2DB20D6037-SPE2DB25FTVC9
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $11,821.02, is for the delivery of the pharmaceutical product "ZEPBOUND 12.5 MG/0.5 ML PEN 0.5ML" and has an ultimate completion date of April 8, 2025.

The award is associated with a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc. with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables.

This contract award does not have a set-aside designation.

Generated 7/7/25, 12:55 PM